Kettunen, Reetta
Taipale, Heidi http://orcid.org/0000-0002-3281-934X
Tolppanen, Anna-Maija
Tanskanen, Antti
Tiihonen, Jari
Hartikainen, Sirpa
Koponen, Marjaana
Funding for this research was provided by:
University of Eastern Finland (UEF) including Kuopio University Hospital
Article History
Received: 8 August 2018
Accepted: 29 October 2018
First Online: 9 November 2018
Compliance with ethical standards
: According to Finnish legislation, no ethics committee approval is required as only register-based data was used and participants were not contacted in any way.
: HT, JT, and AT have participated in research projects funded by Janssen and Eli Lilly with grants paid to the institution where they were employed. AT is a member of Janssen advisory board. JT has served as a consultant to Lundbeck, Organon, Janssen-Cilag, Eli Lilly, AstraZeneca, F. Hoffman-La Roche, and Bristol-Myers Squibb. He has received fees for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline; lecture fees from Janssen-Cilag, Bristol-Myers Squibb, Eli Lilly, Pfizer, Lundbeck, GlaxoSmithKline, AstraZeneca, and Novartis; and grant from Stanley Foundation. JT is a member of advisory board in AstraZeneca, Janssen-Cilag, and Otsuka. MK has received personal research grant from Oy H. Lundbeck Ab foundation outside the submitted work. Other authors declare no conflicts of interest.